ArticleScientific reports2026
Potent LeuBAT inhibitors designed in silico as next-generation duloxetine analogs for enhanced major depressive disorder treatment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major Depressive Disorder (MDD), a leading global health challenge, urgently requires advanced therapeutics to mitigate its widespread impact. In this study, a series of duloxetine (DLX) analogs were designed and evaluated using a comprehensive in silico workflow incorporating quantum chemical calculations, ADMET profiling, molecular docking, and molecular dynamics (MD) simulations. Density Functional Theory (DFT) calculations at the B3LYP/6-311G level were performed to assess electronic properties such as the HOMO-LUMO energy gap, dipole moment, electronegativity, and chemical softness. Among the designed compounds, DLX48 demonstrated superior quantum descriptors while retaining the electronic characteristics of the parent molecule. ADMET predictions using ADMETlab 3.0 and ProTox-II revealed that DLX48 complies with major drug-likeness rules (Lipinski, Pfizer), exhibits improved aqueous solubility (Log S = - 3.21), optimal lipophilicity (Log P = 2.87), and shows no predicted hepatotoxicity or genotoxicity. Molecular docking against the LeuBAT (Δ13 mutant) transporter revealed a significant increase in binding affinity for DLX48 (-12.45 kcal/mol), with an inhibition constant (Ki) of 742.09 pM-indicating markedly enhanced target engagement compared to DLX. Long-timescale MD simulations (300 ns) confirmed the thermodynamic stability and favorable dynamic behavior of the DLX48-LeuBAT complex, supported by lower RMSD/RMSF values, persistent hydrogen bonding, reduced solvent exposure, and constrained conformational fluctuations. Collectively, these in silico findings nominate DLX48 as a promising central nervous system (CNS)-active lead compound with enhanced pharmacological efficacy and a reduced toxicity profile, warranting further preclinical investigation for the treatment of depression and anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.